enGene (ENGN) Stock Forecast & Price Target

$4.93 +0.30 (+6.48%)

As of 04:00 PM Eastern

enGene - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 10 Analyst Ratings

Sell
0

Hold
1

Buy
9

Based on 10 Wall Street analysts who have issued ratings for enGene in the last 12 months, the stock has a consensus rating of "Buy." Out of the 10 analysts, 1 has given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for ENGN.

Consensus Price Target

$25.22
411.61% Upside

According to the 10 analysts' twelve-month price targets for enGene, the average price target is $25.22. The highest price target for ENGN is $34.00, while the lowest price target for ENGN is $7.00. The average price target represents a forecasted upside of 411.61% from the current price of $4.93.

Get the Latest News and Ratings for ENGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for enGene and its competitors.

ENGN Analyst Ratings Over Time

Type	Current Forecast 3/25/24 to 3/25/25	1 Month Ago 2/24/24 to 2/23/25	3 Months Ago 12/26/23 to 12/25/24	1 Year Ago 3/26/23 to 3/25/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	10 Buy rating(s)	3 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$25.22	$25.89	$29.78	$35.50
Forecasted Upside	411.61% Upside	314.69% Upside	371.17% Upside	94.63% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Remove Ads

ENGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ENGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

enGene Stock vs. The Competition

Type	enGene	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.82	2.54
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	438.25% Upside	21,720.57% Upside	17.22% Upside
News Sentiment Rating	Neutral News See Recent ENGN News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/11/2025	Morgan Stanley 3 of 5 stars	Jeffrey Hung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$37.00 ➝ $34.00	+584.10%
3/11/2025	HC Wainwright 1 of 5 stars	A. Maldonado Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00	+377.10%
2/18/2025	Piper Sandler 2 of 5 stars	Allison Bratzel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$26.00	+340.68%
2/14/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Colin Bristow Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$34.00 ➝ $7.00	+12.00%
12/23/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Tuerkcan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$18.00 ➝ $18.00	+208.75%
11/27/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Mccutcheon Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$23.00	+167.44%
11/18/2024	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Tuerkcan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/24/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00	+368.02%
4/22/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$30.00	+102.02%
4/15/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$34.00	+120.78%
2/20/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Foroohar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/20/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$31.00	+91.95%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:59 PM ET.

ENGN Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for enGene is $25.22, with a high forecast of $34.00 and a low forecast of $7.00.
: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for enGene in the last twelve months. There is currently 1 hold rating, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ENGN shares.
: According to analysts, enGene's stock has a predicted upside of 411.61% based on their 12-month stock forecasts.
: Over the previous 90 days, enGene's stock had 1 downgrade by analysts.
: enGene has been rated by research analysts at HC Wainwright, Morgan Stanley, Piper Sandler, and UBS Group in the past 90 days.
: Analysts like enGene more than other "medical" companies. The consensus rating for enGene is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ENGN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:ENGN) was last updated on 3/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

enGene (ENGN) Stock Forecast & Price Target